期刊
MEDICINAL CHEMISTRY RESEARCH
卷 31, 期 2, 页码 232-243出版社
SPRINGER BIRKHAUSER
DOI: 10.1007/s00044-021-02841-3
关键词
COVID-19; Molnupiravir; Mechanism of action; Synthetic pathway; Molecular docking
资金
- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences [400092]
This study reports the development progress of a new oral antiviral drug molnupiravir, including its mechanism of action and the latest synthetic pathway. It is of significant importance for research in related disciplines.
During the COVID-19 pandemic, various drug candidates have been developed, molnupiravir (MK-4482 and EIDD-2801), which is a new orally anti-viral agent under development for the treatment of COVID-19, is under study in the final stage of the clinical trial. Molnupiravir enhances the replication of viral RNA mutations in animals and humans. Due to the high demand for the synthesis of this drug, it was essential to develop an efficient and suitable synthetic pathway from raw material. In this study, molecular docking analysis on molnupiravir is examined also, the mechanism of action (MOA) and the recent synthetic pathway is reported. This review will be helpful to different disciplines such as medicinal chemistry, organic chemistry, biochemistry, and pharmacology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据